Medical Products News

Panel members will include Dr. Ali Said Faqi, MPI Research, Inc., Mr. Bruce Feistner, OSI Pharmaceuticals and Dr. Dorothy Colagiovanni, Replidyne, Inc., with another panel member to be added. Dr. Colagiovanni will also act as moderator. Panelists will discuss pre-clinical, regulatory and clinical issues, as well as stumbling blocks.

CBSA members may attend at no cost. Non-member admission is $50, and a student discount is available.

Longmont LifeScience Thursday, held each quarter, began in 2003, and is designed to provide information and networking opportunities for those interested in the life science industry, including those involved or interested in biotechnology, medical devices, ag biotech, pharmaceuticals, research institutions and life science industries. The Longmont Area Economic Council is a founding sponsor of the event and John Cody, LAEC President, serves on the CBSA Program Committee. Denise Brown, Executive Director of CBSA, has been instrumental in developing new programs for the Association and raising its profile in Colorado.

This program is sponsored by the Longmont Area Economic Council and Pratt Management.

About the Longmont Area Economic Council
The Longmont Area Economic Council exists for the sole purpose of keeping the Longmont area economy strong. This is accomplished specifically by "actively supporting the creation and preservation of quality primary jobs." Primary employers are those who sell the majority of their goods and services outside the region. LAEC is a public/private partnership, governed by a Board of Directors made up of representatives from primary employers, the City of Longmont, and the business community at large. For more information, call (303) 651-0128, email e-mail protected from spam bots, or visit www.longmont.org.

About the Colorado BioScience Assocation
The Colorado BioScience Association is a not-for-profit corporation providing services and support for Colorado’s growing biosciences industry. Colorado is embarking on an aggressive plan to grow the state’s bioscience industry into one of the country’s premier bioscience clusters. CBSA enjoys the support of over 200 member organizations representing a range of bioscience companies dedicated to solving problems and developing products as well as companies providing key services to the bioscience industry and research institutions. CBSA works closely with the state and local policy makers to represent the interests of the bioscience industry. A critical component for Colorado to become one of the country’s top bioscience clusters is a supportive legislative and regulatory environment. The Colorado BioScience Association actively works to achieve these results. For more information, call 720-859-4153, email e-mail protected from spam bots, or visit www.cobioscience.com.

Speaker Bios
Dr. Ali Said Faqi, Director of Developmental & Reproductive Toxicology at MPI Research in Kalamazoo, Michigan. Before joining MPI Research he was a senior Scientist at IITRI in Chicago, Illinois and Allergan Pharmaceuticals in Irvine, California. Dr. Faqi is also an adjunct Professor at the University Palermo, Italy. Dr. Faqi received his DVM degree from the Somali National University in Mogadishu, Somalia and Diploma of Specialization in Experimental Pharmacology at University of Milan in Italy. He received his PhD from the University of Leipzig in Germany. He worked as a Postdoctoral Fellow/Research Scientist at the Free University of Berlin, in Germany, Thomas Jefferson University in Philadelphia and Morehouse School of medicine in Atlanta.

Mr. Bruce Feistner, Regulatory Affairs Manager at OSI Pharmaceuticals. He joined NeXagen Pharmaceuticals in 1993 and has worked through the various permutations of the Boulder company as it evolved from NeXagen to NeXstar Pharmaceuticals to Gilead Sciences and finally OSI Pharmaceuticals. During that period Mr. Feistner has worked primarily with oncology drug products and has witnessed the transformation from traditional chemotherapeutics to targeted therapies. He is responsible for preparing and/or overseeing regulatory submissions for investigational and commercial products on a global basis.

Dr. Dorothy Colagiovanni, novel antibiotic development toxicologist, Replidyne, Inc. Prior to working at Replidyne, she was a Research Investigator at OSI Pharmaceuticals where she was involved with development of targeted cancer therapeutics and managed the toxicology group which conducted GLP compliant studies for regulatory submissions. She has also worked for Amgen in the area of immunotoxicology assessment of novel proteins and at Gilead Sciences in the Anti-Infectives Division. Dr. Colagiovanni attended the University of Vermont and completed a Bachelor of Science degree in Medical Technology. Her graduate training took place at the University of Colorado Health Sciences Center where she earned a doctorate in Molecular Toxicology. She is board certified as a Diplomate of the American Board of Toxicology and has written numerous toxicology documents to support IND submissions and Investigator’s Brochures.